Dysport (abobotulinumtoxinA) / Ipsen - LARVOL DELTA

Early Onset of AbobotulinumtoxinA Effects in Post-Stroke Upper Limb Spasticity: A Prospective Observational Pilot Study. (PubMed, Toxins (Basel)) - "Given the absence of intermediate assessments between 24 h and day 5, the exact timing of treatment onset cannot be determined. A multimodal assessment approach may help characterize early treatment-related changes and provide useful information for future studies investigating the timing of adjunctive rehabilitation interventions."

Journal • Observational data • Cardiovascular • Movement Disorders

EBTox: Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex (clinicaltrials.gov) - P2/3 | N=18 | Completed | Sponsor: University Hospital, Toulouse | Recruiting ➔ Completed

Trial completion

Longitudinal Ultrasonographic Evaluation of Morphologic, Elastographic, Vascular, and Adaptive Muscle Changes Following AbobotulinumtoxinA Injection in Bruxism-Associated Masseter Hypertrophy (EADV 2026) - No abstract available

Dental Disorders

Efficacy of Dysport in the treatment of late onset-lingal dystonia secondary to neuroleptics (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Dystonia • Movement Disorders

Long-term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real-world analysis (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Dystonia • Movement Disorders

TOX PARK: Evaluation of the Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians, Cross-over Study, Double Blind and Placebo-controlled (clinicaltrials.gov) - P3 | N=39 | Not yet recruiting | Sponsor: University Hospital, Toulouse

New P3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

CARBUR: CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity (clinicaltrials.gov) - P=N/A | N=113 | Active, not recruiting | Sponsor: Ipsen | Trial primary completion date: May 2026 ➔ Feb 2027

Trial primary completion date • Movement Disorders

Comparison Between Palpatory and Ultrasound-guided Methods for Botulinum Toxin Administration in Spastic Paraplegia (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Universidade Federal Fluminense

New P4 trial • Genetic Disorders

Changes in P2X4 receptor expression following AbobotulinumtoxinA treatment in patients with chronic migraine: A case series study. (PubMed, Curr J Neurol) - " Findings indicate that P2X4R upregulation may be linked to the therapeutic effects of BoNT-A, while NTRK2 and SRCIN1 appear uninvolved. The trend in P2X4R expression suggests it may serve as a predictive biomarker and therapeutic target, but further validation in larger cohorts is necessary."

Journal • CNS Disorders • Migraine • Pain • NTRK2

Dysport: Regulatory submission for migraine in H2 2026 (Ipsen) - H1 2026 Results

Filing • Migraine

Botulinum toxin A for primary axillary hyperhidrosis: a narrative review. (PubMed, J Med Life) - "Comparative data indicate similar efficacy among onabotulinumtoxinA, incobotulinumtoxinA, and abobotulinumtoxinA when equivalent dosing and standardized mapping techniques are applied. Energy-based modalities-including microwave thermolysis and fractional microneedle radiofrequency-reduce sweating via device-mediated thermal targeting of eccrine glands and show variable comparative outcomes versus intradermal BoNT-A in durability, downtime, and cost. Overall, BoNT-A remains a well-supported first-line injectable therapy for PAH refractory to topical treatment, while further head-to-head and cost-effectiveness studies remain warranted."

Journal • Review • Dermatology

DNHFS: Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients (clinicaltrials.gov) - P3 | N=107 | Completed | Sponsor: Department of Medical Services Ministry of Public Health of Thailand | Not yet recruiting ➔ Completed

Trial completion

Two Toxins, One Disorder: Neurophysiological and Clinical Effects in Caput-Type of Cervical Dystonia at Waning and Peak Response Phases of BoNT-A Therapy. (PubMed, Toxins (Basel)) - "We assessed afferent conduction (captured by CSP parameters), efferent conduction (captured by F-wave parameters) and clinical severity (TWSTRS) in 28 patients with caput-type cervical dystonia during waning (>14 weeks post-injection) and peak (4-6 weeks) phases, comparing onabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO). Overall, BoNT-A treatment phase is better reflected by CSP-derived inhibitory measures than by F-wave indices. TWSTRS improved at peak for both toxins, with no difference between ONA and ABO in clinical change (ΔTWSTRS p = 0.5514)."

Journal • CNS Disorders • Dystonia • Movement Disorders

Botulinum Toxin Type A for the Treatment of Focal Spasticity in Children With Cerebral Palsy in Thailand: A Cost-Utility and Budget Impact Analysis. (PubMed, Value Health Reg Issues) - "Neither SoC + BoNT-A therapy was cost-effective, although both improved spasticity-related quality of life. A 14% price reduction for aboBoNT-A could improve cost-effectiveness. The projected 5-year budget impact was modest across uptake scenarios."

HEOR • Journal • Cerebral Palsy • CNS Disorders • Movement Disorders

Impact of Dysport on PMFF Donor Scar (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Vanderbilt University Medical Center

New P4 trial • Basal Cell Carcinoma • Genetic Disorders • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. (Ipsen Press Release) - "The E-BEOND results represent the first Phase III trial in which a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine. Together with the positive C-BEOND results, BEOND is the first Phase III clinical program to demonstrate efficacy of a botulinum toxin in the prevention of both episodic and chronic migraine...Dysport was well-tolerated. Safety findings observed across both trials were consistent with well-established use of Dysport in approved indications, with no new or unexpected signals identified....Detailed findings from the BEOND program will be presented at a future scientific congress."

P3 data: top line • Migraine

Association of AbobotulinumtoxinA and Skinbooster for Periorbital Wrinkles: A Randomized, Controlled, Double-Blind, Split-Face Study. (PubMed, Aesthetic Plast Surg) - "The association of abobotulinumtoxinA with Restylane® Skinbooster Vital provides enhanced and lasting improvements in severe canthal wrinkles."

Clinical • Journal • Aesthetic Medicine

Pattern Changes and Recurrent Remissions in Cervical Dystonia: Insights from a Long-Term Treated Case. (PubMed, Toxins (Basel)) - "Over time, treatment requirements decreased from higher initial doses (500-700 U abobotulinumtoxinA and up to 130 U onabotulinumtoxinA) to lower maintenance doses of 30-50 U incobotulinumtoxinA/onabotulinumtoxinA, with longer injection intervals and no obvious documented need for dose adjustment to maintain clinical responsiveness. This case highlights the coexistence of pattern changes and recurrent remissions within a single continuously followed patient over an unusually long period. Although a treatment-related mechanism remains speculative and alternative explanations cannot be excluded, the observation underscores the value of prolonged follow-up and individualized treatment strategies in CD."

Journal • CNS Disorders • Dystonia • Movement Disorders

PETRA: Pubalgia and Adductor Tendinopathies Refractory to Medical Treatment (clinicaltrials.gov) - P2 | N=4 | Terminated | Sponsor: University Hospital, Bordeaux | N=20 ➔ 4 | Unknown status ➔ Terminated; target number of patient not reached and lost of financial supplies

Enrollment change • Trial termination

Quality of Life Assessment Using the Leg Activity Measure in Ambulatory Individuals With Leg Spasticity: Findings From a Longitudinal, Observational Study Evaluating the Effectiveness of AbobotulinumtoxinA in Routine Practice. (PubMed, Arch Rehabil Res Clin Transl) - "Repeat lower limb treatment with abobotulinumtoxinA improved QOL as assessed by both symptom-specific and generic instruments. The significant correlations between LegA Part C and EQ-5D-5L support validity of the LegA to assess the impact of treatment on QOL in patients with leg spasticity."

HEOR • Journal • Observational data • Movement Disorders

Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis. (PubMed, J Neural Transm (Vienna)) - "AbobotulinumtoxinA (Abo/BoNT-A), onabotulinumtoxinA (Ona/BoNT-A), incobotulinumtoxinA (Inco/BoNT-A) and lanbotulinumtoxinA (Lan/BoNT-A) were associated with significantly higher odds of ptosis compared with placebo. Differences in ptosis risk may reflect differences in dosing strategies rather than intrinsic differences between BoNT-A formulations. The review protocol was registered in PROSPERO (CRD420261299121)."

Journal • Retrospective data • CNS Disorders

Factors Influencing the Selection of Botulinum Toxin Preparations for the Management of Spasticity. (PubMed, Am J Phys Med Rehabil) - "BoNT formulation selection involves multiple factors with significant practice variability. While economic and institutional considerations influence decisions, clinicians prioritize disease characteristics, clinical expertise, and toxin properties when ranking options. Evidence-based guidelines are needed to reduce practice variation and improve BoNT-based spasticity management."

Journal • Movement Disorders

Enhanced Efficacy of Post-Procedural Skin Care: A Double-Blind, Randomized, Vehicle-Controlled, Split-Face Clinical Study Assessing a Novel Neuropeptide Serum Following Botulinum Toxin Injection. (PubMed, Clin Cosmet Investig Dermatol) - "Botulinum toxins type-A (BTX-A) including onabotulinumtoxinA (Botox Cosmetic®), abobotulinumtoxin A (Dysport®), and incobotulinumtoxinA (Xeomin®) have regulatory approval and are widely used as a highly effective non-surgical treatment for dynamic facial wrinkles. Compared to vehicle, the neuropeptides serum's statistical benefits can be seen as early as 2 weeks prior to BTX-A injection. The study demonstrated that the neuropeptide serum is an effective complementary product that can be used with BTX-A treatments to achieve enhanced results."

Journal • Aesthetic Medicine

The evidence gap for non-onabotulinumtoxinA in migraine prevention: A systematic review of dosing, efficacy, and injection techniques (AHS 2026) - "The available evidence suggests that early negative trials of non-onabotulinumtoxinA in episodic Migraine likely reflect sub-therapeutic dosing rather than lack of efficacy. Higher doses of abobotulinumtoxinA appear promising for chronic Migraine, and incobotulinumtoxinA may offer a viable rescue option for patients previously non-responsive to onabotulinumtoxinA. Simplified injection protocols warrant further investigation."

Clinical • Review • CNS Disorders • Migraine • Pain

Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis. (PubMed, Neurol Ther) - "Patients with CD who initiated therapy on onabotA had comparable switch rates at 12 months but were less likely to switch to another BoNTA at anytime and had lower or comparable costs to incobotA."

HEOR • Journal • Real-world evidence • Retrospective data • CNS Disorders • Dystonia • Movement Disorders